Xeris Biopharma Holdings, Inc.

XERSReported to SECin USCIK 0001867096Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 15. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 15
Form 4 lines at Xeris Biopharma Holdings, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
McCulloch KevinSee RemarksOpen-market sell$250,00025,000 sharesSep 29, 2026McCulloch KevinSee Remarks$250,000Sell · Sep 29Open-market sell25,000Sep 29, 2026
McCulloch KevinSee RemarksOpen-market sell$127,30815,000 sharesSep 1, 2026McCulloch KevinSee Remarks$127,308Sell · Sep 1Open-market sell15,000Sep 1, 2026
Pieper StevenSee RemarksOpen-market sell$42,5005,000 sharesSep 1, 2026Pieper StevenSee Remarks$42,500Sell · Sep 1Open-market sell5,000Sep 1, 2026
Hecht BethSee RemarksOpen-market sell$141,43416,666 sharesSep 1, 2026Hecht BethSee Remarks$141,434Sell · Sep 1Open-market sell16,666Sep 1, 2026
Shannon John Patrick JrSee RemarksAdministrative$296,09236,645 sharesAug 21, 2026Shannon John Patrick JrSee Remarks$296,092Admin · Aug 21Administrative36,645Aug 21, 2026